IL316164A - Intravenous formulation containing istaroxim for the treatment of precardiogenic shock and cardiogenic shock - Google Patents

Intravenous formulation containing istaroxim for the treatment of precardiogenic shock and cardiogenic shock

Info

Publication number
IL316164A
IL316164A IL316164A IL31616424A IL316164A IL 316164 A IL316164 A IL 316164A IL 316164 A IL316164 A IL 316164A IL 31616424 A IL31616424 A IL 31616424A IL 316164 A IL316164 A IL 316164A
Authority
IL
Israel
Prior art keywords
cardiogenic shock
istaroxime
treatment
intravenous formulation
containing intravenous
Prior art date
Application number
IL316164A
Other languages
English (en)
Hebrew (he)
Inventor
Steven Simonson
Original Assignee
Windtree Therapeutics Inc
Steven Simonson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windtree Therapeutics Inc, Steven Simonson filed Critical Windtree Therapeutics Inc
Publication of IL316164A publication Critical patent/IL316164A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL316164A 2022-04-20 2023-04-18 Intravenous formulation containing istaroxim for the treatment of precardiogenic shock and cardiogenic shock IL316164A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263332909P 2022-04-20 2022-04-20
PCT/US2023/018998 WO2023205183A1 (en) 2022-04-20 2023-04-18 Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock

Publications (1)

Publication Number Publication Date
IL316164A true IL316164A (en) 2024-12-01

Family

ID=86331896

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316164A IL316164A (en) 2022-04-20 2023-04-18 Intravenous formulation containing istaroxim for the treatment of precardiogenic shock and cardiogenic shock

Country Status (9)

Country Link
EP (1) EP4511040A1 (enExample)
JP (1) JP2025513337A (enExample)
KR (1) KR20250005343A (enExample)
CN (1) CN119156218A (enExample)
AU (1) AU2023256547A1 (enExample)
CA (1) CA3248625A1 (enExample)
IL (1) IL316164A (enExample)
MX (1) MX2024012948A (enExample)
WO (1) WO2023205183A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025128432A1 (en) * 2023-12-11 2025-06-19 Windtree Therapeutics, Inc. Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1079807A (en) 1912-09-25 1913-11-25 Jonathan S Snyder Coat-closure.
NL95803C (enExample) 1953-12-31 1900-01-01
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
CN1261791A (zh) 1997-07-02 2000-08-02 Sdg有限公司 诊断或治疗用途的靶向脂质体构建物
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
CN103315968B (zh) 2013-06-26 2015-04-01 中国生命药物治疗有限公司 一种注射用粉针剂及其制备方法
CN112118846B (zh) 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Also Published As

Publication number Publication date
MX2024012948A (es) 2024-11-08
EP4511040A1 (en) 2025-02-26
JP2025513337A (ja) 2025-04-24
WO2023205183A1 (en) 2023-10-26
CA3248625A1 (en) 2023-10-26
AU2023256547A1 (en) 2024-11-28
KR20250005343A (ko) 2025-01-09
CN119156218A (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
IL291488A (en) Combination of gene therapy and treatment of right ventricular arrhythmogenic cardiomyopathy
HRP20260212T1 (hr) Pripravci i postupci za liječenje mišićne distrofije
IL290792B1 (en) Preparations and methods for treating viral infections
IL284700A (en) Treatment of conditions of the eyes with similar-angiopoietin 7 inhibitors
SG11202009574RA (en) Combinations of osteopontin and 2'-fucosyllactose for use as medicaments
EP4034218A4 (en) Infusion catheter and methods of use
IL308221A (en) Preparations and methods for treating depression
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
EP4168425A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
IL285921A (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
GB2595513B (en) Treatment of infections
IL290540A (en) Compounds suitable for the treatment and prevention of muscle wasting and other conditions
EP4138852A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
IL319307A (en) Compositions and methods for preventing and treating orthopoxvirus infections
IL289236A (en) Preparations and methods for treating fungal infections
EP3989974A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OCULAR INFECTIONS WITH FILOCICLOVIR
IL277635A (en) Preparations and methods for the treatment of catecholaminergic polymorphic ventricular tachycardia transmitted by dominant inheritance
PT4433065T (pt) Utilização de maribavir no tratamento da infeção por citomegalovírus e respetivos regimes de tratamento
IL289069A (en) Synergistic effect of fxr and ifn agonist for treatment of HBV infection
ES3065215T3 (en) Composition for the treatment and prevention of the esca disease
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
GB2616213B (en) Griseofulvin as an adjunct drug for the treatment of cerebral and severe malaria
HK40115469A (en) Use of maribavir for the treatment of and treatment regimens thereof
HK40085403A (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
HUE066653T2 (hu) Cholangiopathiák kezelése seladelparral